AN2 Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
AN2 Therapeutics, Inc. (ANTX) reported Increase (Decrease) in Accrued Liabilities of -$388.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11
- AN2 Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$103.00K.
- AN2 Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$285.00K.
- AN2 Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$653.00K.
- AN2 Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$249.00K.
- AN2 Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$2.40M.
- AN2 Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$2.23M, a 157.93% decline from fiscal 2023.
- AN2 Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $3.84M, a 122.97% increase from fiscal 2022.
- AN2 Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $1.72M, a 236.72% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$388.00K 10-Q · filed 2026-08-11 | -$1.04M derived: sum of 3 quarters · filed 2026-08-11 | -$1.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$285.00K 10-Q · filed 2026-05-11 | -$938.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.19M derived: sum of 3 quarters · filed 2026-05-11 | -$2.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$653.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$902.00K derived: sum of 2 quarters · filed 2026-03-17 | -$1.99M derived: sum of 3 quarters · filed 2026-08-11 | -$2.40M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.34M derived: sum of 2 quarters · filed 2026-08-11 | -$1.75M 10-Q · filed 2025-11-12 | -$2.22M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.50M 10-Q · filed 2026-08-11 | -$1.97M derived: sum of 3 quarters · filed 2026-08-11 | -$2.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$411.00K 10-Q · filed 2026-05-11 | -$878.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.80M derived: sum of 3 quarters · filed 2026-05-11 | -$2.87M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$1.39M derived: sum of 2 quarters · filed 2026-03-17 | -$2.46M derived: sum of 3 quarters · filed 2026-03-17 | -$2.23M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$922.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.99M derived: sum of 2 quarters · filed 2025-11-12 | -$1.76M 10-Q · filed 2025-11-12 | -$1.64M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$838.00K 10-Q · filed 2025-08-12 | -$721.00K derived: sum of 3 quarters · filed 2025-08-12 | -$600.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $233.00K 10-Q · filed 2025-05-13 | $350.00K derived: sum of 2 quarters · filed 2025-05-13 | $471.00K derived: sum of 3 quarters · filed 2025-05-13 | $2.72M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $238.00K derived: sum of 2 quarters · filed 2025-03-25 | $2.49M derived: sum of 3 quarters · filed 2025-03-25 | $3.84M 10-K · filed 2025-03-25 |
| 2023-09-30 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.37M derived: sum of 2 quarters · filed 2024-11-13 | $3.73M 10-Q · filed 2024-11-13 | $4.76M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $3.61M 10-Q · filed 2024-08-13 | $4.64M derived: sum of 3 quarters · filed 2024-08-13 | $4.65M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.36M 10-Q · filed 2024-05-14 | $2.39M derived: sum of 2 quarters · filed 2024-05-14 | $2.40M derived: sum of 3 quarters · filed 2024-05-14 | $3.02M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.04M derived: sum of 2 quarters · filed 2024-03-29 | $1.66M derived: sum of 3 quarters · filed 2024-03-29 | $1.72M 10-K · filed 2024-03-29 |
| 2022-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $628.00K derived: sum of 2 quarters · filed 2023-11-09 | $692.00K 10-Q · filed 2023-11-09 | $419.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $615.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $679.00K 10-Q · filed 2023-08-10 | $406.00K derived: sum of 3 quarters · filed 2023-08-10 | $701.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $64.00K 10-Q · filed 2023-05-11 | -$209.00K derived: sum of 2 quarters · filed 2023-05-11 | $86.00K derived: sum of 3 quarters · filed 2023-05-11 | $244.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $22.00K derived: sum of 2 quarters · filed 2023-03-29 | $180.00K derived: sum of 3 quarters · filed 2023-03-29 | $512.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $295.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $453.00K derived: sum of 2 quarters · filed 2022-11-09 | $785.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $158.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $490.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $332.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |